SPERO THERAPEUTICS INC (SPRO)
US84833T1034 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 76.29M | 76.33M | 109.10M | 112.60M | 85.20M | |||
| Marketable Securities | N/A | N/A | 0.00 | 33.80M | 41.70M | |||
| Receivables | 53.28M | 50.70M | 1.10M | 2.60M | 6.20M | |||
| Other Current Assets | 2.06M | 4.18M | 3.40M | 8.80M | 6.10M | |||
| Total Current Assets | 131.63M | 131.21M | 113.60M | 157.90M | 139.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.38M | 4.16M | 5.50M | 7.60M | 8.80M | |||
| Other Non-Current Assets | 153.00K | 435.00K | 5.70M | 5.60M | 5.20M | |||
| Total Non-Current Assets | 3.53M | 51.18M | 11.20M | 13.20M | 14.40M | |||
| TOTAL ASSETS | 135.16M | 182.39M | 124.80M | 171.10M | 153.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 17.07M | 8.28M | 10.70M | 15.70M | 13.20M | |||
| Accounts Payable | 6.09M | 1.38M | 600.00K | 1.10M | 1.20M | |||
| Other Current Liabilities | 25.94M | 27.50M | 10.40M | 1.90M | N/A | |||
| Total Current Liabilities | 49.10M | 37.15M | 21.60M | 18.70M | 14.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 48.40M | 0.00 | |||
| Other Non-Current Liabilities | 20.56M | 38.34M | 27.20M | 15.70M | 7.10M | |||
| Total Non-Current Liabilities | 20.56M | 38.34M | 27.30M | 64.10M | 7.10M | |||
| TOTAL LIABILITIES | 69.65M | 75.50M | 48.90M | 82.80M | 21.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -438.75M | -391.07M | -413.90M | -367.50M | -277.70M | |||
| Additional Paid In Capital | 504.20M | 497.91M | 489.80M | 455.70M | 409.70M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 54.00K | 53.00K | 100.00K | 0.00 | 0.00 | |||
| Other Shareholders' Equity | N/A | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 54.31M | 53.00M | 52.50M | 32.40M | 29.30M | |||
| Tangible Book Value per Share | 1.21 | 2.02 | 1.45 | 2.73 | 4.51 | |||
| Total Shareholders' Equity | 65.51M | 106.89M | 75.90M | 88.30M | 132.00M | |||
| TOTAL LIABILITIES AND EQUITY | 135.16M | 182.39M | 124.80M | 171.10M | 153.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | 0.55 | N/A | |||
| Current Ratio | 2.68 | 3.53 | 5.26 | 8.44 | 9.73 | |||
| Return On Assets (ROA) | 2.60% | 12.50% | -37.20% | -52.46% | -51.36% | |||
| Return On Equity (ROE) | 5.36% | 21.34% | -61.16% | -101.65% | -59.72% | |||
| Return On Invested Capital (ROIC) | N/A | 14.57% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | 30.71% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | 30.71% | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21